DADavid Ashirov

David Ashirov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David Ashirov has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Syndecan-4 proteoliposomes enhance revascularization in a rabbit hind limb ischemia model of peripheral ischemia

    by Andrew D Sligar, Gretchen Howe, Julia Goldman, Patricia Felli, Almudena Gómez-Hernández, Eri Takematsu, Austin Veith, Shubh Desai, William J. Riley, Rohan Singeetham, et al.


  • Open Access

    Syndecan-4 Proteoliposomes Enhance Revascularization in a Rabbit Hind Limb Ischemia Model of Peripheral Ischemia

    by Andrew D. Sligar, Gretchen Howe, Julia Goldman, Patricia Felli, Almudena Gómez-Hernández, Eri Takematsu, Austin Veith, Shubh Desai, William J. Riley, Rohan Singeetham, et al.

    Regenerative therapeutics for treating peripheral arterial disease are an appealing strategy for creating more durable solutions for limb ischemia. In this work, we performed preclinical testing of an injectable formulation of syndecan-4 proteoliposomes combined with growth factors as treatment for peripheral ischemia delivered in an alginate hydrogel. We tested this therapy in an advanced model of hindlimb ischemia in rabbits with diabetes and hyperlipidemia. Our studies demonstrate enhancement in vascularity and new blood vessel growth with treatment with syndecan-4 proteoliposomes in combination with FGF-2 or FGF-2/PDGF-BB. The effects of the treatments were particularly effective in enhancing vascularity in the lower limb with a 2-4 increase in blood vessels in the treatment group in comparison to the control group. In addition, we demonstrate that the syndecan-4 proteoliposomes have stability for at least 28 days when stored at 4°C to allow transport and use in the hospital environment. In addition, we performed toxicity studies in the mice and found no toxic effects even when injected at high concentration. Overall, our studies support that syndecan-4 proteoliposomes markedly enhance the therapeutic potential of growth factors in the context of disease and may be promising therapeutics for inducing vascular regeneration in peripheral ischemia. Funding Information: The authors gratefully acknowledge funding through the DOD CDMRP (W81XWH-16-1-0580; W81XWH-16-1-0582) and the National Institutes of Health (1R01HL141761-01) to ABB. Declaration of Interests: The authors have patented the technology presented in this manuscript. Ethics Approval Statement: Studies involving animals were performed with the approval of the University of Texas at Austin and the UTHealth Science Center at Houston Institutional Animal Care and Use Committee (IACUC), the Animal Care and Use Review Office (ACURO) of The United States Army Medical Research and Materiel Command Office of Research Protections, and in accordance with NIH guidelines for animal care.